VolitionRx’s Nu.Q vet cancer test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation.
Heska’s Nu.Q Canine Cancer Screen and Monitor Test will operate on Heska’s proprietary Element i+ Immunodiagnostic Analyzer, a point-of-care platform which provides veterinarians with rapid, accurate, low cost, and easy-to-use on-site testing in the veterinary clinic, to support clinical decision-making and improve patient outcomes.
Dr Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, said: “This is a breakthrough moment for Volition: it is the first time the Nu.Q platform is available outside of centralised laboratory testing. Our mission at Volition is to ensure that our Nucleosomics technology is accessible and affordable worldwide, to detect and monitor disease earlier and improve outcomes. We are delighted to be working with Heska and their remarkable point-of-care technology to enable vets, pets, and pet families to benefit from our innovative technology. We are thrilled to advance towards full commercial launch and license payment milestones.”
Kevin Wilson, Heska's Chief Executive Officer and President said: “We are pleased now to offer our transformative Nu.Q Canine Cancer Screen and Monitor Test at the point of care, which we believe will revolutionise canine cancer patient management. Available now for pre-order, the screen and monitoring test will assist veterinarians to detect cancer early, in the clinic, in minutes, and for under $50, to support clinical decision-making during annual check-ups, regular wellness exams, healthcare interventions, treatment cycles, and remission. While we also offer this technology at the central reference lab, we believe the benefits of point-of-care cancer screening and monitoring are significant and will provide outsized benefits to veterinarians, nursing and technical teams, pets, and pet families.”
The Nu.Q test is to be showcased at the 2023 Western Veterinary Conference in Las Vegas, one of the world’s largest veterinary conferences as the company rolls it out exclusively to the point-of-care, with the global commercial launch planned for early in the second quarter of 2023.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including cancer in both humans and animals. For more information about Volition’s Nu.Q technology go to: www.volition.com.